HCA Q1 2023 Earnings Report
Key Takeaways
HCA Healthcare reported a strong first quarter in 2023, with revenues increasing to $15.591 billion and net income attributable to HCA Healthcare, Inc. totaling $1.363 billion, or $4.85 per diluted share. The company saw increases in same facility admissions and equivalent admissions, reflecting strong demand for its services. HCA also repurchased 3.340 million shares of its common stock at a cost of $846 million and revised its 2023 guidance upwards.
Revenues totaled $15.591 billion, up from $14.945 billion in Q1 2022.
Net income attributable to HCA Healthcare, Inc. reached $1.363 billion, or $4.85 per diluted share, compared to $1.273 billion, or $4.14 per diluted share, in Q1 2022.
Adjusted EBITDA totaled $3.172 billion, compared to $2.944 billion in the first quarter of 2022.
Same facility admissions increased by 4.4 percent and same facility equivalent admissions increased by 7.5 percent compared to the prior year period.
HCA
HCA
Forward Guidance
HCA Healthcare revised its 2023 guidance upwards, with revenue expected to be in the range of $62.5 to $64.5 billion and EPS between $17.25 and $18.55.
Positive Outlook
- Revenues are projected to be between $62.5 billion and $64.5 billion.
- Net income attributable to HCA Healthcare, Inc. is expected to be in the range of $4.750 billion to $5.160 billion.
- Adjusted EBITDA is forecasted to be between $12.1 billion and $12.7 billion.
- Diluted earnings per share are projected to be between $17.25 and $18.55.
- Capital expenditures for 2023, excluding acquisitions, are estimated to be approximately $4.6 billion.
Challenges Ahead
- Guidance is subject to uncertainties and risks, including the impact of the COVID-19 pandemic.
- General economic conditions, including inflation, could impact the company's performance.
- Potential for losses on sales of facilities.
- Possible losses on retirement of debt.
- Potential legal claims costs and impairment of long-lived assets.